Mercer Global Advisors Inc Otonomy, Inc. Transaction History

Mercer Global Advisors Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 11, 2021	SELL	$2.49 - $6.23 $439,353 - $1.1 Million	-176,447 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$3.48 - $6.47 $17,400 - $32,350	5,000 Added 2.92%	176,447 $1.14 Million
Q3 2020 Dec 10, 2020	BUY	$3.16 - $4.36 $15,800 - $21,800	5,000 Added 3.0%	171,447 $694,000
Q2 2020 Aug 10, 2020	BUY	$1.87 - $3.84 $142,048 - $291,694	75,962 Added 83.95%	166,447 $603,000
Q1 2020 May 18, 2020	SELL	$1.58 - $4.06 $74,672 - $191,879	-47,261 Reduced 34.31%	90,485 $178,000
Q4 2019 Feb 13, 2020	BUY	$2.13 - $3.83 $202,350 - $363,850	95,000 Added 222.24%	137,746 $528,000
Q3 2019 Nov 12, 2019	SELL	$2.12 - $2.86 $48,679 - $65,671	-22,962 Reduced 34.95%	42,746 $102,000
Q2 2019 Aug 14, 2019	SELL	$2.35 - $3.09 $46,983 - $61,778	-19,993 Reduced 23.33%	65,708 $181,000
Q1 2019 Apr 23, 2019	BUY	$1.8 - $2.97 $154,261 - $254,531	85,701 New	85,701 $225,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

Stay updated on Mercer Global Advisors Inc with notifications on news.